The fast growth of cell and gene therapies has made it difficult for the global industry to keep up with talent requirements. The volume of clinical trials around the world – approximately 1,200 at this time – puts pressure on manufacturers to scale-up the production of cells and viral vectors. CellCAN, a knowledge mobilization network in cell and gene therapies (CGTs), and CCRM, a leader in developing and commercializing regenerative medicine-based technologies and CGTs, are responding to that challenge by launching the Canadian Advanced Therapies Training Institute (CATTI).